Tyra Biosciences reports 2022 net loss of $55.3M; cash $251.2M; TYRA-300 in clinic for oncology and achondroplasia

Tyra Biosciences, Inc.

Q4 2022 net loss $12.9M vs $9.9M in Q4 2021; full year net loss $55.3M vs $26.3M.
Cash and equivalents $251.2M as of Dec 31, 2022; provides >2 years runway.
Initiated patient dosing with TYRA-300 in Phase 1/2 SURF301 oncology study in Nov 2022.
Expanded TYRA-300 development into achondroplasia; IND planned for Phase 2 in 2024.
FDA cleared IND for TYRA-200 Phase 1 study in FGFR-resistant cholangiocarcinoma; first patient expected 2H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tyra Biosciences, Inc. reported financial results for the quarter and fiscal year ended December 31, 2022.

Period: the quarter and fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 22, 2023, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009166

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.